Seton Pharmaceuticals, LLC and Senores Pharmaceuticals, Inc. announced the launch of Butalbital, Acetaminophen and Caffeine Capsules USP, 50 mg/325 mg/40 mg, a therapeutic equivalent of the reference listed drug Butalbital, Acetaminophen, and Caffeine capsules of Mayne Pharma, Inc. in the U.S. market. The product will be distributed by Seton Pharmaceuticals, LLC.
Butalbital, Acetaminophen and Caffeine Capsules are indicated for the relief of the symptom complex of tension (or muscle contraction) headache.
U.S. annual market size for Butalbital, Acetaminophen and Caffeine Capsules USP, 50 mg/325 mg/40 mg was approximately US$29.18M.